An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Inclusion Criteria: Complete 6 cycles treatment in preceding phase I/II study response (CR, PR, MR or NC) was obtained in 6 cycles treatment during the preceding phase I/II study and investigator considers that the patient is expected to have benefit such as antitumor effect, pain relief or improvement of performance state Patients who did not have Grade >=3 non-hematologic toxicity or Grade 4 hematologic toxicity during the preceding phase I/II study or extension treatment of this study Investigator considers that the patient is expected to have benefit of this drug such as antitumor effect, pain relief or improvement of performance state. Exclusion Criteria: Patient is known to be HBs antigen positive, HCV antibody positive or HIV antibody positive (check is required for patients who received blood product during phase I/II study) Patients who receive G-CSF product or blood transfusion within 7 days before the start of treatment Disease progress was observed during the phase I/II or this study when patients receive recommended dose Patients who suffer Grade >=2 peripheral neuropathy or Grade >=2 neuropathic pain Patient has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, acute ischemia or active conduction system abnormalities.